Latest revenue
$12.4M
as of 2026-03-31
Latest net income
$-5.6M
as of 2026-03-31
Net margin
-45.3%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think AYTU is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $23.6M
- Enterprise value
- $18.7M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.67×
- Dividend yield
- 0.0%
- 52-wk high
- $3.06
- 52-wk low
- $1.65
- Beta
- —
- Shares out
- 10.7M
5-year trend
What this company does
ITEM 1. BUSINESS Company Overview Aytu BioPharma, Inc. (“Aytu,” the “Company,” “we,” “us,” or “our”) is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. We were originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. In March 2021, we changed our name to Aytu BioPharma, Inc. Our common stock trades on the Nasdaq Capital Market LLC (the “Nasdaq”) under the ticker symbol “AYTU.” Our principal office is located at 7900 East Union Avenue, Suite 920, Denver, Colorado…
AI summary unavailable — showing raw filing excerpt
Generated from AYTU's filing dated 2025-09-23
Key risks
ITEM 1A. RISK FACTORS Investing in our securities includes a high degree of risk. You should consider carefully the specific factors discussed below, together with all of the other information contained in this Annual Report. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects would likely be materially and adversely affected. This could cause the market price of our securities to decline and could cause you to lose all or part of your investment. Risks Related to Our Business and Financial Position We have incurred losses to date and can give no assurance of profitability. We have incurred losses in each year since…
AI summary unavailable — showing raw filing excerpt
Generated from AYTU's filing dated 2025-09-23
Profitability
Gross margin
69.0%
2.5%Operating margin
-11.8%
81.8%Net margin
-20.4%
4.4%Return on equity
-71.5%
25.1%Return on assets
-10.9%
18.6%Leverage
Debt / equity
5.55×
70.1%Long-term debt / equity
0.57×
46.4%Debt / assets
84.7%
10.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $12.4M | -32.7% | $-5.6M | -240.7% | -45.3% |
Q4 2025 2025-12-31 | $15.2M | -6.5% | $-8.6M | -1193.8% | -56.8% |
Q3 2025 2025-09-30 | $13.9M | -16.2% | $2.0M | +33.3% | 14.1% |
Q2 2025 2025-06-30 | $15.1M | -50.2% | $-19.8M | -329.2% | -130.9% |
Q1 2025 2025-03-31 | $18.5M | +31.6% | $4.0M | +238.3% | 21.6% |
Q4 2024 2024-12-31 | $16.2M | -13.5% | $788.0K | +458.2% | 4.9% |
Q3 2024 2024-09-30 | $16.6M | -7.0% | $1.5M | +118.2% | 8.9% |
Q2 2024 2024-06-30 | $30.4M | — | $-4.6M | — | -15.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AYTU — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$125.0K
Insider selling
$0
Net activity
+$125.0K
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2025-06-09 | Jarrett Disbrow Chief Business Officer | Purchase | 16,666 | $1.50 | $25.0K | |
| 2025-06-09 | Joshua R. Disbrow Chief Executive Officer | Purchase | 66,666 | $1.50 | $100.0K |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AYTU
Institutional value
$1.4M
Total shares held
659.8K
Distinct holders
19
-19 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 261.1K | $712.9K | — | New |
| 2 | Persistent Asset Partners Ltd | 92.9K | $253.6K | +13.5K (+17.0%) | Added |
| 3 | VANGUARD FIDUCIARY TRUST CO | 47.0K | $128.4K | — | New |
| 4 | DIMENSIONAL FUND ADVISORS LP | 43.6K | $119.0K | +8.2K (+23.3%) | Added |
| 5 | BELLEVUE ASSET MANAGEMENT, LLC | 25.0K | $68.3K | +0 (+0.0%) | No change |
| 6 | BlackRock, Inc. | 22.8K | $62.2K | +0 (+0.0%) | No change |
| 7 | Daytona Street Capital LLC | 10.0K | $26.8K | +0 (+0.0%) | No change |
| 8 | UBS Group AG | 1.7K | $4.5K | -1.4K (-45.5%) | Trimmed |
| 9 | JPMORGAN CHASE & CO | 154 | $405 | — | New |
| 10 | CROWN ADVISORS MANAGEMENT, INC. | 145.0K | $395 | — | New |
| 11 | WELLS FARGO & COMPANY/MN | 127 | $347 | +0 (+0.0%) | No change |
| 12 | GROUP ONE TRADING LLC | 37 | $101 | +0 (+0.0%) | No change |
| 13 | BNP PARIBAS FINANCIAL MARKETS | 23 | $63 | +0 (+0.0%) | No change |
| 14 | SBI Securities Co., Ltd. | 11 | $30 | +0 (+0.0%) | No change |
| 15 | ACADIAN ASSET MANAGEMENT LLC | 10.2K | $27 | +0 (+0.0%) | No change |
| 16 | VISION FINANCIAL MARKETS LLC | 2 | $6 | +0 (+0.0%) | No change |
| 17 | Caitong International Asset Management Co., Ltd | 2 | $5 | — | New |
| 18 | TSFG, LLC | 1 | $0 | +0 (+0.0%) | No change |
| 19 | FNY Investment Advisers, LLC | 90 | $0 | -31.5K (-99.7%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AYTU's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.